fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ASH 2018: Advances in RRMM

Written by | 25 Jan 2019

Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.

ASH 2018: TOURMALINE-MM3 study

Written by | 25 Jan 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.

ASH 2018: Novel agents in combination for relapsed/refractory Hodgkin’s lymphoma: the ECOG-ACRIN E4412 study

Written by | 14 Jan 2019

Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.

ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

Written by | 14 Jan 2019

Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.

WCLC 2018: Variety of approaches can work in oligometastatic disease

Written by | 17 Oct 2018

Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.

WCLC 2018: Accessibility & quality of life: a patient focus at WCLC

Written by | 17 Oct 2018

Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said… read more.

WCLC 2018: PACIFIC: durvalumab results impressive, but not without questions

Written by | 17 Oct 2018

Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.

WCLC 2018: Early ALTA-1L data encouraging for brigatinib

Written by | 17 Oct 2018

The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with… read more.

WCLC 2018: NELSON – CT screening saves lives

Written by | 17 Oct 2018

A randomised, controlled screening trial for lung cancer involving almost 16,000 people in the Netherlands and Belgium found that CT screening produced a 26% reduction in lung cancer… read more.

ASCO 2018: KEYNOTE-042 shows OS

Written by | 20 Aug 2018

First-line treatment with the PD-1 inhibitor pembrolizumab showed an overall survival benefit compared to platinum-based chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer and… read more.

ASCO 2018: Choices for front-line NSCLC

Written by | 20 Aug 2018

With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…

ASCO 2018: Hot topics in lung cancer

Written by | 20 Aug 2018

Hot topics in lung cancer – interviews from ASCO 2018.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.